medigraphic.com

2004, Number s2

<< Back Next >>

Arch Cardiol Mex 2004; 74 (s2)

Anticoagulation treatment in patients with non-ST segment elevation acute coronary syndromes

Juárez HU

Language: Spanish
References: 29
Page: 423-428
PDF size: 60.06 Kb.


ABSTRACT

A number of studies have demonstrated that the low molecular weigth heparin (LMWH) are effective and safe alternative in anticoagulation treatment improving the outcomes in acute coronary syndromes. The pharmacological and pharmacokinetical differences between unfractionated heparin and LMWH, the rational about why this medications can not share criteria for therapeutic interchange in a same clinic scenario are outlined. The results of the trials who had clarified that at this time now are considerated as a first therapeutic choice in unstable angina and no-ST elevation acute coronary syndromes. Another important issues as the time of the treatment after an acute coronary syndrome, the combination with IIb/IIIa inhibitors, the role in high risk groups and the use in coronary intervention procedures.


REFERENCES

  1. Hirsh J, Warkentin TE, Raschke R: Heparin and low molecular weigth heparin. Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114(Suppl 5): 489S-510S.

  2. Weitz JI: Low molecular weigth heparins. N Engl J Med 1997; 337: 688-98.

  3. White HR: Low molecular weigth heparins: Are they the same? British J Hematology 2003; 121: 12-20.

  4. Turpie AGG: Can we differentiate the low molecular weigth heparins? Clin Cardiol 2000; 23(Suppl I): 14-17.

  5. Nigthtingale SL: From de Food and Drug Administration. JAMA 1993; 270: 1672.

  6. Pentalyse Investigators. The Pentua Study. Eur Heart J 2001; 22: 1716-1724.

  7. The FRAXIS Investigators: (FRAxiparine in ischaemic syndrome). Eur Heart J 1999; 20: 1553-1562.

  8. Antman EM, McCabe CH, Gurfinkel EP: Enoxaparin prevents death and ischaemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in acute myocardial infarction (TIMI )11B trial. Circulation 1999; 100: 1593-1601.

  9. Cohen M, Demers C, Gurfinkel EP: A comparison of low molecular heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med 1997; 337: 447-452.

  10. Klein W, Buchwald A, Hills SE: Comparison of low molecular weigth heparin with unfractionated heparin acutely and with placebo for 6 weeks in management of unstable coronary artery disease study. ( FRIC ) Circulation 1997; 96: 61-68.

  11. Antman EM, Cohen M, Radley D: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602-1608.

  12. Kahul S, Shah PK: Low molecular weigth heparin in acute coronary syndrome. Evidence for superior or equivalent efficacy compared with unfractionated heparin? Am Coll Cardiol 2000; 35: 1699-1712.

  13. Elkelboom JW, Anand SS, Malmberg K, Weitz JL, Jinsberg JS, Yusuf S: Unfractionated heparin and low molecular weigth heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355: 1936-1942.

  14. Michalis LK, Katsouras C, Papamichen N: Enoxaparin versus Tinzaparin in non ST segment elevation acute coronary syndromes. The EVET trial. Am Heart J 2003; 146: 304-310.

  15. Cohen M, Theroux P, Weber S: Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999; 71: 273-281.

  16. Cohen M, Theroux P, Borzak S: Randomized double blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST segment elevation acute coronary syndromes treated with tirofiban and aspirin. The ACUTE II study. The antithrombotic combination using tirofiban and enoxaparin. Am Heart J 2002; 144: 470-477.

  17. Ferguson JJ: The use of enoxaparin and Iib/IIIa antagonists in acute coronary syndromes; including PCI: Final results of NICE 3 study. J Am Coll Cardiol 2001; 37(Suppl A): 365ª.

  18. Boersma E, harrington RA, Moliterno DJ: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet 2002; 359: 189-198.

  19. Merlini PA, Bauer KA, Oltrona L: Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-68.

  20. Antman EM, Cohen M, McCabeCH, Goodman SG, Murphy SA, Braunwald E: Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1 year follow-up of TIMI 11 B and ESSENCE. Eur Heart J 2002; 23: 308-314.

  21. The FRISC II Investigators: Long term low molecular mass heparin in unstable coronary artery disease: the Frisc II prospective randomized multicentre study. Lancet 1999; 354: 701-707.

  22. The Frisc II Investigators: Invasive compared with non invasive treatment in coronary artery disease: The Frisc II prospective randomized multicentre study: Fragmin and fast revascularization during instability in coronary artery investigators. Lancet 199; 354: 708-715.

  23. Antman EM, Cohen M, Bernink PJ: The TIMI risk score for unstable angina/non ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-842.

  24. Zilstra F, Hoorntje JC, de Boer MJ: Long term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999; 341: 1413-1419.

  25. Bertrand ME, Simoons M, Fox KA: Management of acute coronary syndromes: Acute coronary syndromes without persistent ST segment elevation; recommendations to the Task Force of European Society of Cardiology. Eur Heart J 2000; 21: 1406-1432.

  26. The thrombolysis in myocardial infarction (TIMI)11A Trial Investigators. Dosing ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol 1997; 29: 1474-1482.

  27. Goodman S, Cohen M, Bigonzi F: Randomized trial of low molecular weigth heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One year results of the ESSENCE study: Efficacy and Safety of Subcutaneous Enoxaparin in non Q wave Coronary Events. J Am Coll Cardiol 2000; 36: 693-698.

  28. Rabah MM, Premmereur J, Graham M: Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 199; 84: 1391-1395.

  29. Choussat R, Montalescost G, Collet JP: A unique low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002; 40: 1943-1950.




2020     |     www.medigraphic.com